Filter by: patients
What is Flecainide?

Flecainide acetate is an antiarrhythmic agent used to prevent or suppress documented life-threatening ventricular arrhythmias; for controlling symptomatic, disabling supraventricular tachycardias in patients without structural heart disease in whom other antiarrhythmic agents fail.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Atrial Fibrillation 8 2 Efficacy_major Efficacy_cant_tell
Other 6 2 Efficacy_major Efficacy_cant_tell
Heart arrhythmias 3 0
Support heart health 2 0
Ventricular Tachycardia 1 1 Efficacy_major
Angina pain 1 0

See all 24 patients currently taking Flecainide

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
1
Mild
0
None
3

Reported Dosages

  50 mg daily 100 mg daily 200 mg daily 300 mg daily
  5 Number of Patients: 5 10 Number of Patients: 10 6 Number of Patients: 6 4 Number of Patients: 4  

Reported Stop Reasons

Why Patients Stopped Taking Flecainide (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 1   Doctor's advice: 50%
Other 1   Other: 50%

See all 2 patients who’ve stopped taking Flecainide

Currently Taking Flecainide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Flecainide

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Flecainide

Always
4 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Flecainide

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
4 100%

Cost

Paid out of pocket

Cost of Flecainide

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.